RAPT Therapeutics Valuation
| RAPT Stock | USD 57.68 0.05 0.09% |
At this time, the entity appears to be overvalued. RAPT Therapeutics holds a recent Real Value of $42.03 per share. The prevailing price of the entity is $57.68. Our model determines the value of RAPT Therapeutics from inspecting the entity fundamentals such as Current Valuation of 1.51 B, return on asset of -0.51, and Shares Owned By Institutions of 64.70 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting RAPT Therapeutics' valuation include:
Price Book 10.9819 | Enterprise Value | Enterprise Value Ebitda (10.73) | Price Sales 411.2189 | Enterprise Value Revenue 677.3673 |
Overvalued
Today
Please note that RAPT Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of RAPT Therapeutics is based on 3 months time horizon. Increasing RAPT Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
RAPT Therapeutics' intrinsic value may or may not be the same as its current market price of 57.68, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 57.68 | Real 42.03 | Target 58.0 | Hype 57.68 | Naive 58.93 |
The intrinsic value of RAPT Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence RAPT Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of RAPT Therapeutics helps investors to forecast how RAPT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of RAPT Therapeutics more accurately as focusing exclusively on RAPT Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use RAPT Therapeutics' intrinsic value based on its ongoing forecasts of RAPT Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against RAPT Therapeutics' closest peers.
RAPT Therapeutics Cash |
|
RAPT Therapeutics Total Value Analysis
RAPT Therapeutics is at this time projected to have valuation of 1.51 B with market capitalization of 1.67 B, debt of 4.49 M, and cash on hands of 207.34 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the RAPT Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.51 B | 1.67 B | 4.49 M | 207.34 M |
RAPT Therapeutics Asset Utilization
One of the ways to look at asset utilization of RAPT is to check how much profit was generated for every dollar of assets it reports. RAPT Therapeutics holds a negative application of assets of -0.51 pct., losing $0.005135 for each dollar of assets held by the entity. Unsuccessful asset utilization implies the company is being less competent with each dollar of assets it holds. Put it differently, asset utilization of RAPT Therapeutics shows how unproductive it operates for each dollar spent on its assets.RAPT Therapeutics Profitability Analysis
Based on RAPT Therapeutics' profitability indicators, RAPT Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess RAPT Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-03-31 | Previous Quarter -17.6 M | Current Value -17.6 M | Quarterly Volatility 9.5 M |
For RAPT Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of RAPT Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well RAPT Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between RAPT Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of RAPT Therapeutics over time as well as its relative position and ranking within its peers.
RAPT Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of RAPT Therapeutics is estimated to be -0.61875 with future projections ranging from a low of -0.7375 to a high of -0.2475. RAPT Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -11.66. Please be aware that the consensus of earnings estimates for RAPT Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.RAPT Therapeutics Earnings Estimation Breakdown
The calculation of RAPT Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of RAPT Therapeutics is estimated to be -0.61875 with the future projection ranging from a low of -0.7375 to a high of -0.2475. Please be aware that this consensus of annual earnings estimates for RAPT Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.74 Lowest | Expected EPS | -0.25 Highest |
RAPT Therapeutics Earnings Projection Consensus
Suppose the current estimates of RAPT Therapeutics' value are higher than the current market price of the RAPT Therapeutics stock. In this case, investors may conclude that RAPT Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and RAPT Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 9 | 34.27% | -0.65 | -0.61875 | -11.66 |
RAPT Therapeutics Ownership Allocation
RAPT Therapeutics owns a total of 28.96 Million outstanding shares. Over half of RAPT Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the entity is less than the current market value, you may not be able to make money on it.RAPT Therapeutics Profitability Analysis
Net Loss for the year was (129.87 M) with profit before overhead, payroll, taxes, and interest of 1.53 M.About RAPT Therapeutics Valuation
The stock valuation mechanism determines RAPT Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of RAPT Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of RAPT Therapeutics. We calculate exposure to RAPT Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of RAPT Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.2 M | -3 M | |
| Pretax Profit Margin | (63.14) | (59.98) | |
| Operating Profit Margin | (64.61) | (61.38) | |
| Net Loss | (63.14) | (59.98) |
RAPT Therapeutics Current Valuation Indicators
RAPT Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final RAPT Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as RAPT Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use RAPT Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes RAPT Therapeutics' worth.Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.